Clinical Trial Update: Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ABT-510 for refractory lymphoma has completed. The provided snippet references the trial status but does not include efficacy or safety…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• ABT-510 (ABT-510)

Snippet

Sponsor: Abbott | Conditions: Lymphoma, Non-Hodgkin, Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED